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A B S T R A C T
Huntington disease (HD) is an autosomal dominant, neurodegenerative disease caused by a CAG repeat expansion within the coding sequence of the HTT gene,
resulting in a highly toxic protein with an expanded polyglutamine stretch that forms typical protein aggregates throughout the brain. We generated human induced
pluripotent stem cells (hiPSCs) from two HD patients using non-integrating Sendai virus (SeV). The hiPSCs display a normal karyotype, express all pluripotency
markers, have the same CAG repeat expansion as the original fibroblasts and are able to differentiate into the three germ layers in vitro.
1. Resource utility
The newly generated hiPSCs are useful to study HD disease me-
chanisms. Furthermore, these cells can be used for disease modelling
and drug discovery studies.
2. Resource details
Huntington Disease (HD) is an autosomal dominant, neurodegen-
erative disease, clinically characterized by motor disturbances, espe-
cially chorea (i.e. involuntary and unpredictable body movements),
behavioral and psychiatric symptoms and cognitive decline (Roos,
2010). As the disease progresses, degeneration can be seen throughout
the brain, but the main affected brain regions are the striatum and
cerebral cortex (Gusella et al., 1983). HD is caused by a CAG repeat
expansion in the first exon of the huntingtin (HTT) gene on chromo-
some 4p16.3. The HTT RNA is translated into a highly toxic huntingtin
protein with an expanded stretch of glutamine amino acids that ag-
gregates throughout the brain.
Skin biopsies were obtained from two symptomatic HD patients; a
51 year old male (CAG repeat 18/46, age of onset 47) and a 49 year old
female (CAG repeat 19/46, age of onset 47). The obtained skin fibro-
blasts were succesfully reprogrammed into hiPSCs using a replication-
defective and persistent Sendai virus (SeV) vector installed with OCT4,
SOX2, KLF4 and c-Myc (Nishimura et al., 2011). The hiPSC clones de-
rived from the male were named LUMCi007-A and B and the hiPSCs
derived from the female were named LUMCi008-A, B and C (Table 1).
All hiPSC clones showed typical hiPSC-like morphology with small and
tightly packed cells, a high nucleus to cytoplasm ratio and well defined
nucleoli (Fig. 1A) and were SeV negative at passage 5 as shown by
immunofluorescent staining (Supplementary Fig. S1A) and RT-qPCR
(data not shown). All clones stained positive for pluripotency markers
OCT3/4, NANOG and SSEA-4 (Fig. 1B). Accordingly, the hiPSCs
showed, compared to the original fibroblasts, upregulated expression of
pluripotency genes OCT3/4, NANOG and SOX2 (Fig. 1C). A routine
Global Screening Array (GSA) showed no major allelic changes in the
hiPSC clones, tested at passage 5–6 (Fig. 1D). Furthermore, the newly
generated hiPSCs were identical to their original fibroblasts as shown
by comparison of the allelic calls (Supplementary Fig. S1B). The CAG
repeat size of the new hiPSC lines was confirmed by PCR (Fig. 1E) and
fragment analysis (data not shown). Trilineage in vitro differentiation of
all clones led to expression of the endodermal marker Sry-related HMG
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T
box 17 (SOX17), the mesodermal marker smooth muscle actin (SMA),
the ectodermal marker β3-tubulin (TUBB3) as confirmed by immuno-
fluorescent staining (Fig. 1F). Finally, all cells tested negative for my-
coplasma (Supplementary Fig. S1C). All the above mentioned data are
presented in Table 2.
3. Materials and methods
3.1. Ethical statement
This study was approved by the LUMC scientific ethical committee
and informed consent was obtained from the two HD patients
(NL45478.058.13/P13.080).
3.2. Generation of hiPSCs
A skin biopsy was obtained from a 51 year old male and a 49 year
old female. Both with symptomatic HD. After dissection, fibroblasts
were cultured in DMEM/F12 medium containing Glutamax, 10% Foetal
Bovine Serum (FBS), Non-Essential Amino Acids (NEAA), 2-mercap-
toethanol, Pen/Strep (all Gibco) and fresh 0.01mg/ml vitamin C
(Sigma) at 37 °C and 5% CO2. Fibroblasts were expanded to passage 3
and subsequently used for reprogramming. For this, 1× 105 fibroblasts
were transduced with 7.5 MOI SeVdp(KOSM)302 L (Nishimura et al.,
2011) and seeded on irradiated mouse embryonic fibroblasts (MEFs) in
fibroblast medium. The next day, medium was changed to DMEM/F12
medium containing Glutamax, 20% KnockOut Serum Replacement
(KOSR), Non-Essential Amino Acids (NEAA), 2-mercaptoethanol, Pen/
Strep (Gibco) and 10 ng/ml bFGF (Peprotech) until hiPSC colonies
formed after approximately 3 weeks. hiPSC colonies were excised
manually and expanded on Vitronectin XF coated plates in TESR-E8
medium (STEMCELL Technologies), resulting in 2 and 3 clones of both
patient cell lines. iPSCs were further cultured on Matrigel (Corning)
coated plates, using mTeSR1 medium (STEMCELL Technologies). Pas-
saging was performed using a 5min incubation with ReLeSR (STEMC-
ELL Technologies) at 37 °C. iPSCs were passaged 1:10–1:20 every
5–7 days and cultured at 37 °C in 5% CO2.
3.3. Trilineage differentiation in vitro of hiPSCs
After incubation with Gentle Cell Dissociation Reagent (STEMCELL
Technologies), undifferentiated hiPSC colonies were harvested and
plated on Matrigel (Corning) coated glass coverslips according to the
STEMdiff™ Trilineage Differentiation Kit protocol (STEMCELL
Technologies). Medium was changed daily and hiPSCs were fixed with
2% paraformaldehyde (PFA) for immunofluorescent stainings after 5
(endoderm and mesoderm) and 7 days (ectoderm).
3.4. Immunofluorescent staining
After fixation in 2% PFA for 30min at RT, the hiPSCs were per-
meabilized with 0.1% Triton X-100 for 1 h at RT. Next, the cells were
incubated with blocking buffer (4% normal swine serum (NSS, DAKO))
for 1 h at RT. Primary antibody labeling, diluted in 4% NSS, was per-
formed O/N at 4 °C. After washing, the cells were incubated with sec-
ondary fluorescent antibodies for 1 h at RT. DAPI was used as a nuclear
staining. Antibodies are listed in Table 3. Images were obtained on a
Leica TCS SP8 microscope.
3.5. RNA isolation and RT-qPCR
RNA isolation was performed using the ReliaPrep™ Miniprep System
(Promega). In short, 500 ng RNA was used per reaction for cDNA
synthesis, using the transcriptor first strand cDNA synthesis kit (Roche).
RT-qPCR reactions were run, in 3 biological and 3 technical triplicates,
on a LightCycler© 480 Real-Time PCR System (Roche), using SensiMix
SYBR Hi-ROX kit (Bioline). Cycle parameters were: 10min at 95 °C and
45 cycles of 95 °C for 10 s, 60 °C for 30 s and 72 °C for 20 s. CT-values
were normalized to GAPDH, using the ΔΔCT-method. HiPSC line 114–2
was used as a positive control. As a negative control, fibroblast line 2B
was used (Buijsen et al., 2018). Primer sequences are listed in Table 3.
3.6. Genomic DNA isolation
Genomic DNA isolation was performed using the Wizard Genomic
DNA Purification Kit (Promega), according to manufacturer's instruc-
tions.
3.7. Repeat length PCR
The CAG repeat in the first exon of the HTT gene was amplified to
confirm the genotype of the hiPSCs. Cycle parameters were: 4min at
95 °C and 35 cycles of 30 s at 95 °C, 30 s at 59 °C and 70 s at 72 °C, ended
by 7min at 72 °C. The PCR products were run on an ABI 3730 auto-
matic DNA sequencer (Applied Biosystems, Foster City, CA, USA). As a
control, hiPSC line 114–2 was used (Buijsen et al., 2018). Primers are
listed in Table 3.
Table 1
Summary of lines.
iPSC line names Abbreviation in figures Gender Age Ethnicity Genotype of locus (#CAG repeats) Disease
LUMCi007-A 151–1 Male 51 Caucasian 18/46 Huntington disease
LUMCi007-B 151–5 Male 51 Caucasian 18/46 Huntington disease
LUMCi008-A 152–2 Female 49 Caucasian 19/46 Huntington disease
LUMCi008-B 152–3 Female 49 Caucasian 19/46 Huntington disease
LUMCi008-C 152–4 Female 49 Caucasian 19/46 Huntington disease
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Fig. 1.
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3.8. Fragment length analysis
Fragment length analysis was performed with OneTaq Master Mix
(New England Biolabs) on an ABI genetic analyser (ThermoFisher).
Cycle parameters were: 5min at 94 °C and 35 cycles of 30 s 94 °C, 1min
60 °C and 2min 68 °C. Primers are listed in Table 3.
3.9. Mycoplasma detection
To test the presence of mycoplasma, the MycoAlert™ Mycoplasma
Detection Kit (Lonza) was used, according to manufacturer's instruc-
tions.
3.10. Global screening array
A Global screening array (GSA) (Illumina) was used according to
standard protocols, followed by an analysis in GenomeStudio software
(Illumina). The GenomeStudio Final reports were used to analyze and
visualize the results in Nexus Discovery (BioDiscovery El Segundo). A
report resolution of 50 kb was used to analyze the data for chromo-
somal aberrations. To compare the patient fibroblasts with the gener-
ated hiPSCs, the array final reports were selected as input for an R
script. Using statistics we determined whether the allelic calls of the
fibroblasts and hiPSCs matched, mismatched or failed.
3.11. Key resources table
Unique stem cell lines i-
dentifier
LUMCi007-A
LUMCi007-B
LUMCi008-A
LUMCi008-B
LUMCi008-C
Alternative names of ste-
m cell lines
LUMCi007-A: LUMC0151iHD01 and 151–1
LUMCi007-B: LUMC0151iHD05 and 151–5
LUMCi008-A: LUMC0152iHD02 and 152–2
LUMCi008-B: LUMC0152iHD03 and 152–3
LUMCi008-C: LUMC0152iHD04 and 152–4
Institution Leiden University Medical Center (LUMC), Leiden, The
Netherlands
Contact information of
distributor
Dr. Willeke M.C. van Roon-Mom, W.M.C.van_Roon@
lumc.nl
Type of cell lines hiPSC
Origin Human
Cell source Skin fibroblasts
Clonality Clonal
Method of reprogram-
ming
Non-integrating Sendai virus
Multiline rationale 2 disease cell lines (2 and 3 clones per line)
Gene modification Yes
Type of modification Hereditary
Associated disease Huntington disease
Gene/locus HTT/4p16.3
Method of modification N/A
Name of transgene or re-
sistance
N/A
Inducible/constitutive s-
ystem
N/A
Date archived/stock date June 2018
Cell line repository/bank https://hpscreg.eu/cell-line/LUMCi007-A
https://hpscreg.eu/cell-line/LUMCi007-B
https://hpscreg.eu/cell-line/LUMCi008-A
https://hpscreg.eu/cell-line/LUMCi008-B
https://hpscreg.eu/cell-line/LUMCi008-C
Ethical approval NL45478.058.13/P13.080, Medical Ethical Committee
(MEC), Leiden University Medical Center (LUMC).
Informed consent was obtained from both HD patients.
Table 2
Characterization and validation.
Classification Test Result Data
Morphology Brightfield microscopy Normal morphology Fig. 1, panel A
Phenotype Qualitative analysis of
immunofluorescent staining
Expression of pluripotency markers NANOG, SSEA-4,
Oct-3/4
Fig. 1, panel B
Quantitative analysis by RT-qPCR Expression of pluripotency markers NANOG, SOX2,
Oct-3/4
Fig. 1, panel C
Genotype GSAMD24 v2 Illumina Infinium SNP
array 760 k
CNV report resolution 50 kb: No major copy number
variations or allelic changes
Fig. 1, panel D
Identity GSAMD24 v2 Illumina Infinium SNP
array 760 k
Fibroblasts and hiPSCs have >99,99% identical SNPs Summarized data in figure S1, panel B. Raw data
available with the authors
Mutation analysis Repeat length PCR and fragment
analysis
Fibroblasts and derived hiPSCs have identical CAG
repeat lengths
Fig. 1, panel E (PCR) and data not shown, but
available from author (fragment analysis)
Southern Blot OR WGS N/A
Microbiology and virology Mycoplasma Mycoplasma testing by luminescence: negative Fig. S1, panel C.
Differentiation potential Qualitative analysis of
immunofluorescent staining
Positive staining of germ layer markers SOX17
(endoderm), SMA (mesoderm) and TUBB3 (ectoderm)
Fig. 1, panel F
Donor screening N/A
Genotype additional info Blood group genotyping N/A
HLA tissue typing N/A
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